incretin mimetic agents glp 1 receptor agonists Clinical Focus on GLP-1 in Type 2 Diabetes Mellitus Mechanisms of action and therapeutic

Biomedical Reports

Exendin has a short half-life

Questions to ask Can we start at a lower dose and adjust it slowly based on my response? What markers will we track to know if the dose is working? Whats the plan if I need to increase? How does this interact with my other medications? (Especially important if youre on HRT for menopause.) What to expect Many telehealth providers now offer low-dose GLP-1 programs

Metformin received FDA approval in 1994 for type 2 diabetes and with its beneficial effect on glycated hemoglobin (HbA1c), efficacy, and safety being wellestablished, 3 , 4 , 5 it became the recommended firstline choice for patients with type 2 diabetes in 2005

Despite their significant clinical potential, they are associated with certain limitations, including suboptimal pharmacokinetics and patient adherence challenges, necessitating the development of advanced drug delivery systems to optimize efficacy and improve compliance

What Patients Need to Know Navigating side effects and knowing when to seek help can greatly improve your experience with GLP-1 medications